Advertisement

Continuing Benefit of Zoledronic Acid in Preventing Skeletal Complications in Patients with Bone Metastases

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Purpose

      We previously reported the efficacy of zoledronic acid 4 mg versus placebo (every 3 weeks for 24 months) for the prevention of skeletal-related events (SREs) in men with advanced prostate cancer and bone metastases. We conducted several retrospective exploratory analyses to determine whether zoledronic acid has continuing efficacy during long-term treatment.

      Patients and Methods

      This report included analysis of the occurrence of SREs during the extension phase only (months 16-24), analysis of skeletal complications excluding the first SRE at 15 months (core phase), and stratified analysis of patients by history of SREs before study entry.

      Results

      Patients (N = 422) were randomized to receive zoledronic acid 4 mg or placebo. For the 132 patients who entered the extension phase, zoledronic acid significantly delayed the onset of first SRE (P = .009) and decreased the risk of developing an SRE by 53% compared with placebo (P = .022). Among all 422 patients, zoledronic acid significantly reduced the incidence of a second on-study SRE (P = .017) and significantly delayed the median time to second SRE compared with placebo (P = .006) at 15 months. Among 144 patients (34%) with a history of SREs before study entry, zoledronic acid significantly reduced the skeletal morbidity rate by 65% (P = .036) and reduced the overall risk of developing an SRE by 40% (P = .028) compared with placebo at 24 months.

      Conclusion

      This analysis confirms our previously reported results and suggests that long-term treatment with zoledronic acid provides continuing clinical benefit in patients with advanced prostate cancer, even after the occurrence of SREs.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Weinfurt KP
        • Li Y
        • Castel LD
        • et al.
        The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.
        Ann Oncol. 2005; 16: 579-584
        • Saad F
        • Gleason DM
        • Murray R
        • et al.
        Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
        J Natl Cancer Inst. 2004; 96: 879-882
        • LoRusso P
        Analysis of skeletal-related events in breast cancer and response to therapy.
        Semin Oncol. 2001; 28: 22-27
        • Rosen LS
        • Gordon D
        • Kaminski M
        • et al.
        Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
        Cancer. 2003; 98: 1735-1744
        • Berenson JR
        • Lichtenstein A
        • Porter L
        • et al.
        Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. For the Myeloma Aredia Study Group.
        N Engl J Med. 1996; 334: 488-493
        • Hortobagyi GN
        • Theriault RL
        • Lipton A
        • et al.
        Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
        J Clin Oncol. 1998; 16: 2038-2044
        • Lipton A
        • Theriault RL
        • Hortobagyi GN
        • et al.
        Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
        Cancer. 2000; 88: 1082-1090
        • Rosen LS
        • Gordon D
        • Kaminski M
        • et al.
        Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
        Cancer J. 2001; 7: 377-387
        • Saad F
        Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone.
        Clin Prostate Cancer. 2002; 1: 145-152
        • Saad F
        • Gleason DM
        • Murray R
        • et al.
        A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
        J Natl Cancer Inst. 2002; 94: 1458-1468
        • Kaminski M
        • Rosen L
        • Gordon D
        • et al.
        Zoledronic acid versus pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications.
        Proc Am Soc Clin Oncol. 2004; 23 (Abstract #857).: 90
      1. Major PP, Cook RJ, Chen BL, et al. Survival-adjusted multiple event analysis of skeletal complications from bone metastases: a comprehensive analysis of treatment benefit. Presented at: 4th International Conference on Cancer-Induced Bone Diseases; December 7-9, 2003. San Antonio, TX. Abstract #84.

      2. Major PP, Cook RJ, Chen B-L, et al. Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Presented at: What Is New in Bisphosphonates? Seventh Workshop on Bisphosphonates—From the Laboratory to the Patient; March 24-26, 2004; Davos, Switzerland. Poster #71.

        • Michaelson MD
        • Smith MR
        Bisphosphonates for treatment and prevention of bone metastases.
        J Clin Oncol. 2005; 23: 8219-8224
        • Andersen PK
        • Gill RD
        Cox's regression model for counting processes: a large sample study.
        Ann Stat. 1982; 10: 1100-1120
        • Saad F
        • Sternberg CN
        Multidisciplinary management of bone complica tions in prostate cancer and optimizing outcomes of bisphosphonate therapy.
        Nat Clin Pract Urol. 2007; 4: S3-S13
      3. Conte PF, Rosen LS, Gordon D, et al. Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma: analysis of patients at high risk for skeletal complications. Presented at: 29th European Society for Medical Oncology Congress; October 29-November 2, 2004; Vienna, Austria. Abstract #463PD.

        • Hirsh V
        • Tchekmedyian NS
        • Rosen LS
        • et al.
        Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
        Clin Lung Cancer. 2004; 6: 170-174
        • Major PP
        • Cook R
        Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
        Am J Clin Oncol. 2002; 25: S10-S18
        • Major PP
        • Cook RJ
        • Chen B
        • et al.
        Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone.
        Proc Am Soc Clin Oncol. 2003; 22 (Abstract #3062).: 762
        • Jemal A
        • Siegel R
        • Ward E
        • et al.
        Cancer statistics, 2006.
        CA Cancer J Clin. 2006; 56: 106-130